亿帆医药：未来公司将一如既往地重视并加强研发创新

Core Viewpoint - The company has been focusing on the research and development of large molecule biopharmaceuticals and small molecule chemical drugs since 2015, aiming to enter the innovative drug market through self-research and collaborative research efforts [1] Group 1: R&D and Innovation - The company has increased its investment in R&D and talent acquisition to gradually penetrate the innovative drug sector [1] - The innovative drug Yili Shou has successfully launched in China, the United States, and Europe, with its commercial value in China becoming increasingly evident [1] - The company has accumulated valuable experience over more than a decade in R&D innovation, particularly in overseas clinical trials, registration, and commercialization [1] Group 2: Future Strategy - The company emphasizes the importance of not only enhancing and validating its R&D capabilities but also ensuring that innovative products quickly enter the market to realize commercial value [1] - Future efforts will continue to focus on R&D innovation, with a more cautious and targeted approach in areas such as oncology, dermatology, and orthopedics [1] - While concentrating on the Chinese market, the company will leverage its initial achievements in internationalization to also address overseas markets, particularly in Southeast Asia [1]